Baseline clinical characteristics
| . | Eligible (n = 81), no. (%) . | Ineligible (n = 26), no. (%) . | All (n = 107), no. (%) . |
|---|---|---|---|
| Median age, y (range) | 60 (21-82) | 64 (29-81) | 62 (21-82) |
| Age ≥ 60 y | 42 (52) | 16 (62) | 58 (54) |
| Sex, female | 35 (43) | 13 (50) | 48 (45) |
| PS 0 or 1 | 72 (89) | 22 (85) | 94 (88) |
| Stage III or IV | 65 (80) | 21 (81) | 86 (80) |
| Elevated LDH | 59 (73) | 13 (50) | 72 (67) |
| ≥ 2 extranodal sites | 22 (27) | 10 (39) | 32 (30) |
| IPI | |||
| 0-1 | 18 (22) | 7 (27) | 25 (23) |
| 2 | 23 (28) | 4 (15) | 27 (25) |
| 3 | 30 (37) | 11 (42) | 41 (38) |
| 4-5 | 10 (12) | 4 (15) | 14 (13) |
| 0-2 | 41 (51) | 11 (42) | 52 (49) |
| 3-5 | 40 (49) | 15 (58) | 55 (51) |
| B symptoms | 35 (43) | 10 (39) | 45 (42) |
| Bulky disease (> 10 cm) | 16 (20) | 3 (12) | 19 (18) |
| . | Eligible (n = 81), no. (%) . | Ineligible (n = 26), no. (%) . | All (n = 107), no. (%) . |
|---|---|---|---|
| Median age, y (range) | 60 (21-82) | 64 (29-81) | 62 (21-82) |
| Age ≥ 60 y | 42 (52) | 16 (62) | 58 (54) |
| Sex, female | 35 (43) | 13 (50) | 48 (45) |
| PS 0 or 1 | 72 (89) | 22 (85) | 94 (88) |
| Stage III or IV | 65 (80) | 21 (81) | 86 (80) |
| Elevated LDH | 59 (73) | 13 (50) | 72 (67) |
| ≥ 2 extranodal sites | 22 (27) | 10 (39) | 32 (30) |
| IPI | |||
| 0-1 | 18 (22) | 7 (27) | 25 (23) |
| 2 | 23 (28) | 4 (15) | 27 (25) |
| 3 | 30 (37) | 11 (42) | 41 (38) |
| 4-5 | 10 (12) | 4 (15) | 14 (13) |
| 0-2 | 41 (51) | 11 (42) | 52 (49) |
| 3-5 | 40 (49) | 15 (58) | 55 (51) |
| B symptoms | 35 (43) | 10 (39) | 45 (42) |
| Bulky disease (> 10 cm) | 16 (20) | 3 (12) | 19 (18) |